23. Novo Nordisk A/S, a Danish firm, sells insulin and other drugs worldwide. Activella, an estrogen and
progestin hormone replacement therapy sold by Novo-Nordisk, is examined using 33 quarters of data
Y = -204 + . 34X1 – .17X2
(17.0) (-1.71)
Where Y is quarterly sales of Activella, X1 is the Novo’s advertising of the hormone therapy, and X2 is
advertising of a similar product by Eli Lilly and Company, Novo-Nordisk’s chief competitor. The pa-
rentheses contain t-values. Addition information is: Durbin-Watson = 1.9 and R2 = .89.
Using the data for Novo-Nordisk, which is correct?
a. Both X1 and X2 are statistically significant.
b. Neither X1 nor X2 are statistically significant.
c. X1 is statistically significant but X2 is not statistically significant.
d. X1 is not statistically significant but X2 is statistically significant.
e. The Durbin-Watson statistic shows significant problems with autocorrelation
24. In which of the following econometric problems do we find Durbin-Watson statistic being far away
from 2.0?
a. the identification problem
b. autocorrelation
c. multicollinearity
d. heteroscedasticity
e. agency problems
25. When there is multicollinearity in an estimated regression equation,
a. the coefficients are likely to be small.
b. the t-statistics are likely to be small even though the R2 is large.
c. the coefficient of determination is likely to be small.
d. the problem of omitted variables is likely.
e. the error terms will tend to have a cyclical pattern.
26. When two or more “independent” variables are highly correlated, then we have:
a. the identification problem
b. multicollinearity
c. autocorrelation
d. heteroscedasticity
e. complementary products